To determine the efficacy of blue versus blue-green phototherapy using new light sources with narrow luminous spectra. The devices made of highintensity gallium nitride light-emitting diodes (LEDs) were also compared to conventional halogen-quartz bulbs phototherapy.
INTRODUCTION
Phototherapy is the standard of care for treatment of neonatal hyperbilirubinemia. 1 The efficacy of phototherapy is dependent on the absorption of light photons by the bilirubin molecules. However, only light of certain colors or wavelengths can be absorbed by bilirubin. Since bilirubin is a yellow pigment, during phototherapy, the blue and green light is best absorbed by the bilirubin molecule. 2 When broad-spectrum white light is used for treatment, only a fraction of the light is acting on the bilirubin. 3 Moreover, bilirubin does not absorb the different colors of light equally. Blue light at about 450 nm is absorbed most readily, while green light is less well absorbed. 2 However, in order for the light to be effective, it must penetrate the newborn's skin.
Longer wavelength light, such as green light, is expected to penetrate the infant's skin deeper. It is still controversial whether the use of green light has any advantage over blue light. [4] [5] [6] [7] [8] [9] [10] This disparity may be attributed, in part, to the fact that the previous studies have compared light sources that generate relatively broadspectrum light. Furthermore, inappropriate radiometry may have been used, thereby confounding the standardization of irradiance measurement.
We have developed a new high-intensity phototherapy light source using recently introduced high-intensity gallium nitride light-emitting diodes (LEDs). 11 This device has a narrow luminous spectrum, and therefore allows for the first time to compare blue (peak 459 nm) versus blue-green (peak 505 nm) phototherapy.
The aim of this study was to compare, at similar light intensities, the efficacy of narrow spectral band blue and blue-green gallium nitride LED light versus conventional halogenquartz phototherapy lamps.
MATERIALS AND METHODS
A total of 114 jaundiced, but otherwise healthy term infants were prospectively randomized to either LED (n ¼ 47) or conventional phototherapy (n ¼ 57). The LED group was further randomized to either blue (n ¼ 25) or blue-green phototherapy (n ¼ 22). The treatment group assignment was based on a computer-generated random table. Entry criteria to phototherapy followed the American Academy of Pediatrics' Practice Parameter. 1 Phototherapy was discontinued when at least two consecutive total serum bilirubin (TSB) measurements showed no increase in TSB levels. The patients were enrolled from May 1998 through February 1999 at Bikur-Cholim and Misgav-Ladach University affiliated community hospitals in Jerusalem. The study was approved by the Institute's Human Investigation Committee and consent for inclusion was obtained from one or both parents before randomization into the study or control groups.
The gallium nitride LED phototherapy device was developed and custom-built at the Neonatal and Developmental Medicine Laboratory of the Department of Pediatrics at Stanford University. The overhead device with six focused arrays, each with 100 blue or blue-green LEDs, generated an irradiance of >200 mW/cm 2 /nm at 10 cm. The blue LEDs (NSPB-500S, Nichia Chemical Industries, Ltd, Tokoshima, Japan) had a peak wavelength at 459 nm and a half-spectral width of 22 nm with a 151 half-angle directivity. The half-spectral width presents the wavelength at which the light power intensity drops by half, while the half-angle directivity reflects the angle at which the light irradiance drops by half. Both measures reflect the optical physical characteristics of the LEDs used in this study. The blue-green LEDs (NSPB-590S, Nichia Chemical Industries, Ltd., Tokoshima, Japan) have a peak wavelength at 505 nm and a half-spectral width of 38 nm with a 101 half-angle directivity. Conventional phototherapy was administered to the control group according to our usual nursery protocol using standard phototherapy units (Microlites, Model PTL 68-1, Series 02, Air Shields, Hatboro, PA), equipped with three halogen-quartz bulbs (EXZ 50W 12V, Phillips, Germany). As the aim of the study was to test the efficacy and safety of using phototherapy devices with a very narrow wavelength band, we placed the LED devices at a distance that provided light intensity within the measured limits of our conventional phototherapy device, that is, 5-8 mW/cm 2 /nm. Irradiance was measured at the clinical setting with a phototherapy radiometer (Olympic Bilimeter, Mark II, Olympic Medical Corporation, Seattle, WA), with peak sensitivity at 450 nm.
The infants were placed in open cribs, unclothed except for a diaper, and with their eyes covered. All infants were breast-fed, with only occasional formula supplementation. TSB was determined in heel stick capillary blood when the newborn appeared clinically jaundiced, and the test was repeated every 4 to 6 hours. The decision on discontinuation of treatment was made every 4 to 6 hours based on the TSB levels. The TSB was measured using a Unistat Bilirubinometer (AO Scientific Instruments, Buffalo, NY) by determining absorbancy at 460 nm with correction for hemoglobin contamination (550 nm).
The statistical analysis included Student's t-test, w 2 test and calculation of 95% confidence limits for least-square means using a General Linear Models Procedure (SAS System). Linear regression analysis (SAS Institute Inc., Cary, NC) was used to adjust for the possible confounding effect of multiple factors, including newborns' sex, birth weight, gestational age, premature rupture of membranes, maternal smoking, and study hospital. Sample size calculations were based on the hypothesis that the blue-green LEDs would be 50% more efficient than the blue LED for phototherapy. Based on our previous study, 12 where the mean rate of decrease in TSB for the blue LED phototherapy was À3.2 mmol/hour with an SD of 1.6, the expected mean rate of decrease in TSB with the use of blue-green LEDs was estimated as À4.8 mmol/hour with an SD of 1.6. Setting a significance level of 0.05 and a power of 0.80, the calculated sample size required was determined to be 16 for each study group.
RESULTS
The distribution of maternal ethnic origin (Ashkenazi Jews 61.8%; Sephardic Jews 23.5%, and Arabic 14.7%), smoking, the rate of premature rupture of membranes, and the use of analgesia and oxytocin during labor were similar for the three study groups. The mean±SD gestational age (weeks) was 39.3±1.4 for the blue LED group, 39.9±1.4 for the blue-green LED group, and 39.4±1.7 for conventional phototherapy group. The mean±SD postnatal age (hours) at initiation of treatment was 48.4±27.2 for the blue LED group, 46.2±31.3 for the blue-green LED group, and 60.4±40.8 for the conventional phototherapy group.
No statistically significant differences were found for the characteristics of the infants, including birth weight, Apgar scores, meconium-stained amniotic fluid, cephalohematoma, Coombs' positive tests, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, and breast-feeding. The mean TSB at initiation of treatment did not differ between the study and control groups ( Table 1 ). The minimal, mean, and maximal TSB levels during phototherapy, as well as the TSB concentrations when the infants were taken off treatment, were comparable in the two groups ( Table 1 ). The duration of phototherapy and the rate of decrease in TSB were not statistically different ( Table 2 ). The peak-to-trough fluctuation index, a measure of the variability in the TSB concentrations over the study period, was similar in the three study groups ( Table 2) .
The average rate of decrease in TSB (slope), after adjustment by a linear regression analysis for confounding factors, was À3.61 mmol/hour (95% confidence limits À5.47, À1.75) in the 25 newborns receiving blue LED phototherapy compared with À2.57 mmol/hour (À4.32, À0.82) in the 22 newborns treated with blue-green LED phototherapy and À3.42 mmol/hour (À5.02, À1.81) in the 57 newborns who received conventional phototherapy.
No side effects, such as erythema, were noted in any of the newborns. The nurses who cared for the infants did not complain of nausea or dizziness when caring for the babies under the blue LED light. However, both nurses and parents noted that the bluegreen lights gave a more disturbing hue to the newborn's skin than the blue or halogen-quartz lamps.
DISCUSSION
Phototherapy with blue-green LEDs was found to be less effective than either blue LEDs or conventional halogen-quartz phototherapy. Although this difference did not reach statistical significance, the lower efficacy of blue-green phototherapy is consistent with our recent in vitro observations. 11 We compared the in vitro efficacy of LEDs and found that blue light was the most effective in degrading bilirubin by 28% of dark control, followed by blue-green (18% of control), and then white light (14% of control). Green light was the least effective (11% of control).
The efficacy of blue versus green phototherapy, and its correlation with in vitro studies, has been subject of conflicting reports for over two decades. [4] [5] [6] [7] [8] [9] [10] Data obtained in in vitro investigations 13 and in Gunn rat experiments 14 suggested that green fluorescent light has a low efficiency in lowering bilirubin concentrations. However, clinical studies on the effect of green fluorescent light on the rate of bilirubin photodegradation showed it to be of superior, 5 similar 6,8 or inferior 7 efficiency when compared with blue fluorescent light.
One explanation for the apparent discrepancies among these clinical trials [5] [6] [7] [8] is that the greater skin penetration of green light may offset in vivo its lower efficacy in vitro. Longer wavelengths are able to penetrate deeper into the skin than shorter wavelengths. 15 This phenomenon has the effect of shifting the effective absorption spectrum of bilirubin from blue to green. Green and blue-green light may also be more effectively absorbed in vivo by albuminbound bilirubin. 16 Albumin, which in vivo binds bilirubin, also binds with long-chain fatty acids. 15 This cobinding results in a shift in the absorption maximum of bilirubin to longer wavelengths. 17 In addition, it has been noted that the absorption spectrum of bilirubin may be modified when bound to skin constituents 18 and by the filtering action of skin layers. 16 The apparent efficacy of the green fluorescent lamps used in some of these clinical studies can be attributed to the not unimportant contribution of blue light present in these lamps. 19 Earlier studies used lamps with less discrete blue wavelengths, with a strong narrow mercury emission band at 436 nm, and weaker bands at 365, 405, and 546 nm. [4] [5] [6] [7] [8] [9] [10] In contrast, blue and bluegreen LEDs provide high-intensity monochromatic light of a relatively narrow wavelength band compared to the previously tested blue or green spectrum phototherapy devices. Thus, the use of LEDs allows, for the first time, clinical investigation of specific spectral components of the commonly used polychromatic lamps.
In this study, it was decided to compare blue-green LEDs, rather than green LEDs, to blue LEDs and conventional halogen-quartz lamps, in accordance with our previous in vitro efficacy studies. 11 Furthermore, Donzelli et al. 9 presented preliminary data suggesting that a unique narrow-spectrum blue-green fluorescent lamp with a peak emission at 480 nm was more effective than Special Blue lamps. The high phototherapeutic efficiency of blue-green light was attributed to the combined effects of the increase from blue to green of the quantum yield, of lumirubin, responsible for the quickest pigment clearance in newborns. In addition, they suggested that a corresponding decrease of ZE-BR quantum yield, and the filtering effects of the skin, may result in attenuation of more blue than green light. 9 Phototherapy is considered one of the safest treatment methods for newborns. 1, 3 However, the biologic effects of blue lights on cells in vitro have long been a subject for concern. 20 Blue light generated by fluorescent lamps has been reported to induce singlestrand breaks in the DNA of cells in culture in the absence of bilirubin. 21 During irradiation of bilirubin solutions with blue and green phototherapy light, long-lived toxic photoproducts were formed under in vitro conditions. 22 It was suggested that green light exposure favors the production of lumirubin, while blue light causes more DNA damage and cytotoxicity. 23 However, more recent in vitro studies demonstrated that green fluorescent phototherapy of hyperbilirubinemia may also cause both skin and immune system damage. 19 At present, it remains to be proven whether genotoxic effects observed have clinical implications and if they occur when LED light is used.
The use of green lamps has been reported to cause severe erythema and tanning in the initial 200 hours of phototherapy. 10 However, this unexpected finding was caused, according to Tan, 10 by the small ultraviolet component of the emission spectrum of the green lamps used in his study. The fact that such side effect were not found among our subjects when using highly selective narrowspectrum blue-green LEDs supports Tan's explanation.
In one study, it was noted that when green and blue fluorescent lamps were used for phototherapy, all nurses complained of giddiness and half complained of nausea. 10 The attending personnel, who found the green and blue lamps equally disturbing, also reported temporary blurring of vision. 10 Vecchi et al. 6 felt that green lamps are better tolerated by the nursing staff. Our nursing staff did not experience such complaints when using either blue or blue-green LEDs. We believe that this difference can be attributed to the typical flickering glare of the conventional lamps. In contrast, solid-state LEDs use direct current, and therefore the flickering that may be responsible for the sensation of nausea and vertigo is absent.
The introduction of the blue-green fluorescent lamp in 1995 was implied to be the first significant improvement of phototherapy efficiency since the development and introduction of the specialblue lamp by Sisson in 1970. 9 We have recently shown that blue gallium nitride LEDs are as effective as conventional phototherapy in the treatment of neonatal hyperbilirubinemia, despite their very narrow spectral light at the blue range. 12 In the present study, we took advantage of the narrow spectrum of the LEDs in order to reassess the controversial efficacy of green versus blue phototherapy. [4] [5] [6] [7] [8] [9] [10] Notwithstanding theoretical reasoning for better penetration of green and better absorption of blue light, we found no statistically significant difference in the efficacy of blue-green light over either blue or white light.
The new LED phototherapy devices investigated in the current study were not found to be of higher efficacy when applied using relatively low irradiance levels. However, it must be remembered that much higher irradiance levels are likely to be clinically used in the future. In fact, LED phototherapy devices can provide significantly higher light irradiance levels compared to all currently available fiberoptic and conventional systems. Furthermore, LED phototherapy devices have several additional advantages including, being very power-efficient, durable, portable and lightweight. The LEDs generate little heat, and therefore the phototherapy device can be placed at close proximity to the baby.
